BVS · Nasdaq · CIK 0001665988
Bioventus Inc.
Bioventus Inc.’s most recent SEC filing in our snapshot is a Form SCHEDULE 13G/A filed on Oct 27, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $568.1M and net income of $22.7M, according to its XBRL data on EDGAR. Its EDGAR record lists 25 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- Bioventus Inc.
- Ticker
- BVS
- SEC Central Index Key (CIK)
- 0001665988
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus (code 3841)
- Business address
- DURHAM, NC
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- SEC filer category
- Accelerated filer<br>Emerging growth company
- Position in SEC ticker list
- #2425 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from Bioventus Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $430.9M | $512.1M | $512.3M | $573.3M | $568.1M |
| Net income | $19.4M | -$158.7M | -$156.2M | -$36.1M | $22.7M |
| Diluted EPS | -$0.15 | -$2.59 | -$2.49 | -$0.56 | $0.33 |
| Total assets | $1.2B | $1.4B | $810.9M | $728.0M | $683.6M |
| Cash and equivalents | $43.9M | $30.2M | $37.0M | $41.6M | $51.2M |
XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Mar 5, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Aug 5, 2026 | 10-Q | Quarterly report· period Jun 27, 2026 | Document · Index |
| Aug 5, 2026 | 8-K | Results of operations; Other events· period Aug 5, 2026 | Document · Index |
| Apr 22, 2026 | DEF 14A | Definitive proxy statement· period Dec 31, 2025 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about Bioventus Inc., by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Oct 27, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Aug 5, 2026 | 10-Q | Quarterly report· period Jun 27, 2026 | Document · Index |
| Aug 5, 2026 | 8-K | Results of operations; Other events· period Aug 5, 2026 | Document · Index |
| Jul 27, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Jun 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026 | Document · Index |
| Jun 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026 | Document · Index |
| Jun 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026 | Document · Index |
| Jun 4, 2026 | 8-K | Shareholder vote results· period Jun 3, 2026 | Document · Index |
| Jun 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026 | Document · Index |
| Jun 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026 | Document · Index |
| Jun 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026 | Document · Index |
| Jun 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026 | Document · Index |
| Jun 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026 | Document · Index |
| Jun 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026 | Document · Index |
| Jun 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 2, 2026 | Document · Index |
| May 29, 2026 | SD | Specialized disclosure report (conflict minerals) | Document · Index |
| May 21, 2026 | 8-K | Regulation FD disclosure· period May 21, 2026 | Document · Index |
| May 6, 2026 | 10-Q | Quarterly report· period Mar 28, 2026 | Document · Index |
| May 6, 2026 | 8-K | Results of operations· period May 6, 2026 | Document · Index |
| Apr 22, 2026 | ARS | ARS· period Dec 31, 2025 | Document · Index |
| Apr 22, 2026 | DEFA14A | Additional proxy soliciting materials | Document · Index |
| Apr 22, 2026 | DEF 14A | Definitive proxy statement· period Dec 31, 2025 | Document · Index |
| Apr 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Apr 10, 2026 | Document · Index |
| Apr 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Apr 10, 2026 | Document · Index |
| Apr 14, 2026 | 4/A | Statement of changes in beneficial ownership (insider trade)· period Apr 1, 2021 | Document · Index |
| Apr 14, 2026 | 4/A | Statement of changes in beneficial ownership (insider trade)· period Feb 11, 2021 | Document · Index |
| Apr 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Apr 10, 2026 | Document · Index |
| Mar 24, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 20, 2026 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 14, 2025 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 14, 2025 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 14, 2025 | Document · Index |
| Mar 17, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 14, 2025 | Document · Index |
| Mar 13, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 11, 2026 | Document · Index |
| Mar 11, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Mar 5, 2026 | S-8 | Registration of employee benefit plan securities | Document · Index |
| Mar 5, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Mar 5, 2026 | 8-K | Results of operations· period Mar 5, 2026 | Document · Index |
| Feb 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Feb 15, 2026 | Document · Index |
| Feb 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Feb 15, 2026 | Document · Index |
| Feb 18, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Feb 15, 2026 | Document · Index |
Insider filing activity
25 Form 4 filings appear in Bioventus Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in Surgical & Medical Instruments & Apparatus
- SYK STRYKER CORP
- MMM 3M CO
- BSX BOSTON SCIENTIFIC CORP
- BDX BECTON DICKINSON & CO
- MDLN Medline Inc.
- RMD RESMED INC
- DXCM DEXCOM INC
- WST WEST PHARMACEUTICAL SERVICES INC
All 51 companies in Surgical & Medical Instruments & Apparatus· Companies headquartered in North Carolina
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001665988 and XBRL company facts. Bioventus Inc. on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement